In Depth 3 Nov 2022 What’s on the horizon for gene editing-based therapies? Gene editing has come far in the past decade. However, the field is still finding its feet regarding challenges such as drug delivery, regulation and competition with first-generation gene therapies. Gene editing is a sizzling hot topic in the biotech industry, powered by advances in genetic tools such as CRISPR, TALENs and zinc-finger nucleases. Gene […] November 3, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 VectorBuilder to build gene delivery campus after $57M funding Gene delivery technology company VectorBuilder Inc. has announced the completion of $57 million in funding. The funding, co-led by Legend Capital, will support the construction of VectorBuilder’s new Gene Delivery Research and Manufacturing Campus, and further boost the company’s R&D capabilities and global business presence. VectorBuilder was established in 2014 to commercialize its novel e-commerce […] November 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 Replay Bio launches HSV gene therapy company to target retinal eye disease Replay Bio has announced the launch of Eudora, an HSV (herpes simplex virus) gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Eudora’s co-founders Joe Glorioso, Mark Blumenkranz, David Schaffer, and Vinit Mahajan, are entrepreneurs who have worked in […] October 31, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 ABL and RD-Biotech to partner on cell and gene therapy manufacturing French companies ABL and RD-Biotech have signed a strategic partnership to cover cell and gene therapy (C>) GMP manufacturing. ABL, is a contract development and manufacturing organization (CDMO) that specializes in the development and manufacturing of solutions for biopharma, including viruses for gene therapies, oncolytic viruses and vaccine candidates. RD-Biotech is a CRO (contract research […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2022 Syncona to acquire Applied Genetic Technologies Corporation Healthcare company Syncona Limited says its newly established portfolio company has agreed to acquire, by a tender offer, all outstanding shares of Applied Genetic Technologies Corporation (AGTC). AGTC is a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an […] October 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 20 Oct 2022 Opportunities and challenges for cell and gene therapy investments Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […] October 20, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 Xcell Biosciences and aCGT Vector pushing ahead with cell and gene therapies Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, and aCGT Vector, a point-of-care cell and gene therapy-as-a-service (TaaS) company, are collaborating to improve manufacturing and analytic procedures to develop personalized cell and gene therapies for cancer patients. aCGT Vector will provide its point-of-care, GMP-licensed manufacturing platform to validate Xcellbio’s […] October 13, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2022 The biggest private biotech investments in September 2022 The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […] October 11, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Alexion, AstraZeneca Rare Disease to acquire genomic medicine company LogicBio Therapeutics LogicBio Therapeutics, Inc. has entered into a definitive agreement under which Alexion, AstraZeneca Rare Disease (Alexion) will acquire LogicBio. The proposed acquisition brings LogicBio’s technology, experienced rare disease R&D team, and expertise in pre-clinical development to support Alexion’s growth in genomic medicines. Fred Chereau, president and chief executive officer at LogicBio, said: “We are excited […] October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 29 Sep 2022 Removing binding sites for an oncogene can slow cancer cell growth, researchers say Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers from the University of Helsinki have discovered. They have found a mechanism by which an oncogene commonly activated in cancer patients affects the growth rate of cells. In the future, the findings can help in developing new treatments that could […] September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Promising MND drug slows disease progression Scientists in the U.K. believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care. Results from a phase 3 clinical trial showed significant physical benefits for patients after 12 months. Researchers from the Sheffield Institute for Translational Neuroscience (SITraN) found that patients with a faulty SOD1 […] September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 Bioreactor platform launched to support process development for cell and gene therapy A medical technology company, today announced the launch of a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector. Terumo Blood and Cell Technologies (Terumo BCT) named its Quantum Flex Cell Expansion System, after identifying the industry’s need for earlier automation to potentially limit additional and […] September 20, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email